Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 21 | 26 | +5 |
| Shares | 4.10M | 4.66M | +560.8K (+13.7%) |
| Value | $7.78M | $6.85M | −$934.0K (−12.0%) |
New holders (9)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lynwood Capital Management Inc. | 255,000 | $375.0K | 0.36% |
| Renaissance Technologies LLC | 201,200 | $296.0K | 0.00% |
| Retirement Planning Co of New England, Inc. | 147,331 | $216.0K | 0.11% |
| State Street Corp | 56,900 | $84.0K | 0.00% |
| Two Sigma Investments, LP | 11,500 | $17.0K | 0.00% |
| K.J. Harrison & Partners Inc | 11,300 | $17.0K | 0.00% |
| Mystic Asset Management, Inc. | 2,275 | $3.00K | 0.00% |
| Bank of America Corp | 31 | $0 | 0.00% |
| Morgan Stanley | 2 | $0 | 0.00% |
Sold out (4)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Millennium Management LLC | 101,278 | $192.0K |
| Goldman Sachs Group Inc | 27,895 | $53.0K |
| Envestnet Asset Management Inc | 10,988 | $21.0K |
| Rockefeller Capital Management L.P. | 1,500 | $2.00K |